On February 22, 2020, Bio-Techne Corporation (NASDAQ: TECH) announced an agreement with Thermo Fisher Scientific to exclusively complete development of and commercialize the ExoTRU kidney transplant rejection test developed by Exosome Diagnostics, a Bio-Techne brand. ExoTRU is a non-invasive multigene urine-based liquid biopsy assay that provides critical allograft health information to assist clinician decision-making in managing kidney transplant patients and optimizing patient care. The assay has the potential to discriminate between T-cell-mediated rejection (TCMR) and antibody-mediated rejection (ABMR), which is critical to improving patient management and outcomes. ExoTRU was developed in collaboration with the Azzi Laboratory at the Transplantation Research Center at Brigham and Women's Hospital, Harvard Medical School.
Login Or Register To Read Full Story